Drugdocs | Revcovi

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Revcovi

Chemical Name	elapegademase-lvlr
Dosage Form	Injection (intramuscular; 0.2 mg/kg, 0.4 mg/kg)
Drug Class	Oligonucleotides
System	Blood
Company	Leadiant Biosciences, Inc.
Approval Year	2018

Indication

To treat adenosine deaminase severe combined immunity deficiency.

Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Revcovi (Elapegademase-lvlr) Prescribing Information	2018	Leadiant Biosciences, Inc., Gaithersburg, MD

Document Title	Year	Source
A study of Ezn-2279 (polyethylene glycol recombinant adenosine deaminase [PEG-rADA]) administered as a weekly intramuscular injection in patients with adenosine deaminase (ADA)-deficient combined immunodeficiency.	2020	Leadiant Biosciences, Inc.